Stockscreener 앱 받기
1.25
2.46%
0.03
시간 외 거래:
1.25
전일 마감가:
$1.22
열려 있는:
$1.2
하루 거래량:
261.31K
Relative Volume:
0.36
시가총액:
$39.06M
수익:
-
순이익/손실:
$-51.50M
주가수익비율:
-0.3125
EPS:
-4
순현금흐름:
$-47.10M
1주 성능:
-3.10%
1개월 성능:
-16.67%
6개월 성능:
-76.19%
1년 성능:
-87.11%
1일 변동 폭
$1.1859
$1.31
1주일 범위
$1.145
$1.42
52주 변동 폭
$0.87
$10.21
아웃룩 테라퓨틱스 Stock (OTLK) Company Profile
명칭
Outlook Therapeutics Inc
전화
(609) 619-3990
주소
111 S. WOOD AVENUE, ISELIN, NJ
OTLK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.25 | 39.06M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
아웃룩 테라퓨틱스 Stock (OTLK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-02 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-03-27 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-02-15 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2024-01-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-12-27 | 업그레이드 | CapitalOne | Equal Weight → Overweight |
| 2023-08-31 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2023-08-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-30 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2023-08-30 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-08-30 | 다운그레이드 | CapitalOne | Overweight → Equal Weight |
| 2023-08-30 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-07-13 | 개시 | CapitalOne | Overweight |
| 2023-04-03 | 개시 | Guggenheim | Buy |
| 2023-02-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-10-31 | 개시 | BTIG Research | Buy |
| 2022-09-13 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-11 | 개시 | Ladenburg Thalmann | Buy |
| 2019-05-16 | 개시 | Oppenheimer | Outperform |
| 2019-04-22 | 개시 | Ascendiant Capital Markets | Buy |
모두보기
아웃룩 테라퓨틱스 주식(OTLK)의 최신 뉴스
Charles Schwab Investment Management Inc. Sells 15,411 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Bought by Bank of New York Mellon Corp - Defense World
Head-To-Head Comparison: Cabaletta Bio (NASDAQ:CABA) vs. Outlook Therapeutics (NASDAQ:OTLK) - Defense World
Outlook Therapeutics Files Prospectus Covering Offer & Resale By Selling Stockholders Of Up To 21.7 Million Shares Of Common Stock - Marketscreener.com
Outlook Therapeutics expands share authorization - Investing.com Australia
Outlook Therapeutics Issues Convertible Note to Avondale - TipRanks
Outlook Therapeutics expands share authorization By Investing.com - Investing.com UK
Rhumbline Advisers Purchases 174,896 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
INVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
SHAREHOLDER ALERT: Potential Recovery for Outlook Therapeutics, Inc. (OTLK) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
SHAREHOLDER ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire
INVESTOR ALERT: Contact Levi & Korsinsky Before January 2, 2024 to Discuss Your RightsOTLK - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOTLK - ACCESS Newswire
Outlook Therapeutics® Re-Submits Biologics License - GlobeNewswire
Outlook Therapeutics Resubmits BLA For ONS-5010, A Proposed Treatment For Wet AMD - Nasdaq
Outlook Therapeutics Resubmits Biologics License Application By Investing.com - Investing.com South Africa
Outlook Therapeutics Resubmits BLA For ONS-5010 To FDA In Wet AMD - Nasdaq
Outlook Therapeutics Resubmits Biologics License Application - Investing.com
Can Outlook's Eye Treatment Win FDA Approval Despite Missing Primary Endpoint? - StockTitan
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Outlook Therapeutics, Inc.(OTLK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Outlook Therapeutics (NASDAQ:OTLK) Given New $24.00 Price Target at Ascendiant Capital Markets - Defense World
HC Wainwright Issues Pessimistic Forecast for OTLK Earnings - MarketBeat
Equities Analysts Offer Predictions for OTLK Q1 Earnings - MarketBeat
vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga
HC Wainwright Has Pessimistic Outlook of OTLK Q2 Earnings - Defense World
What is HC Wainwright’s Estimate for OTLK Q1 Earnings? - Defense World
Outlook Therapeutics® Participates in the Virtual Investor 'Top 5 for '25” On-Demand Conference - The Manila Times
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
Can This First-Ever Approved Ophthalmic Bevacizumab Transform Eye Treatment in 2025? - StockTitan
Outlook Therapeutics' (OTLK) Neutral Rating Reaffirmed at Chardan Capital - MarketBeat
Outlook Therapeutics (NASDAQ:OTLK) Given New $3.00 Price Target at HC Wainwright - MarketBeat
Outlook Therapeutics (NASDAQ:OTLK) Price Target Cut to $3.00 by Analysts at HC Wainwright - Defense World
Outlook Therapeutics’ (OTLK) Neutral Rating Reaffirmed at Chardan Capital - Armenian Reporter
Outlook Therapeutics (NASDAQ:OTLK) Given “Neutral” Rating at Chardan Capital - Defense World
Outlook Therapeutics (NASDAQ:OTLK) Announces Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
Outlook Therapeutics stock target cut to $3 at H.C. Wainwright By Investing.com - Investing.com Nigeria
Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Outlook Therapeutics stock target cut to $3 at H.C. Wainwright - Investing.com
Outlook Therapeutics (NASDAQ:OTLK) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
ONS-5010 shows promise in wet AMD treatment, matching Lucentis - MSN
Outlook Therapeutics Reports Strong Earnings and Strategic Progress - MSN
Analyzing Scilex (NASDAQ:SCLX) and Outlook Therapeutics (NASDAQ:OTLK) - Defense World
Outlook Therapeutics, Inc. SEC 10-Q Report - TradingView
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewswire
Outlook Therapeutics Reports Financial Results For First Quarter Of 2025 -February 14, 2025 at 09:07 am EST - Marketscreener.com
Outlook Therapeutics Secures Funding and Board Restructures - MSN
아웃룩 테라퓨틱스 (OTLK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):